Daily Anesthesiology Research Analysis
Analyzed 102 papers and selected 3 impactful papers.
Summary
Three impactful anesthesiology-related studies stood out: a PNAS preclinical study showing flavonoid permeation enhancers can turn ultra-potent local anesthetics into long-acting, nonopioid analgesia; a multicenter prospective cohort in JAMA Pediatrics identifying GFAP and NfL as candidate real-time neurologic biomarkers in children on ECMO; and a randomized trial in Frontiers in Pediatrics demonstrating lung-protective ventilation reduces postoperative atelectasis in neonates.
Research Themes
- Long-acting nonopioid local anesthesia via chemical permeation enhancement
- Biomarker-guided neurologic monitoring in pediatric ECMO
- Lung-protective ventilation strategies in neonatal anesthesia
Selected Articles
1. Extended local anesthesia enabled by flavonoid permeation enhancers.
Selected flavonoids (puerarin, naringenin, kaempferol) act as safe chemical permeation enhancers that markedly increase penetration of site-1 sodium channel blockers and extend nerve block 4- to 25-fold. Liposomal coencapsulation of tetrodotoxin with puerarin yielded single-injection local anesthesia lasting over 25 days with minimal tissue toxicity.
Impact: This introduces a broadly applicable, low-toxicity platform for long-acting, nonopioid local anesthesia, addressing a major clinical need in perioperative and chronic pain management.
Clinical Implications: If translated clinically, flavonoid-based permeation enhancement and liposomal coformulation could enable single-injection, weeks-long local anesthesia, reducing opioid exposure and repeat procedures. Safety profiling and dose-finding will be key to clinical adoption.
Key Findings
- Flavonoids (puerarin, naringenin, kaempferol) prolonged site-1 sodium channel blocker nerve block 4–25×.
- Mechanistic models showed increased penetration across the tympanic membrane and peri-neural barriers, consistent with chemical permeation enhancement.
- Coencapsulation of tetrodotoxin with puerarin in liposomes produced local anesthesia lasting >25 days after a single injection with minimal tissue toxicity versus conventional enhancers.
Methodological Strengths
- Multiple complementary models (tympanic membrane permeation and sciatic nerve distribution) support mechanistic inference.
- Evaluation of tissue toxicity relative to conventional permeation enhancers and demonstration of liposomal delivery synergy.
Limitations
- Preclinical study in animal/tissue models; human pharmacokinetics, safety, and immunogenicity are unknown.
- Long-term neurotoxicity and systemic exposure thresholds require comprehensive evaluation before clinical use.
Future Directions: Proceed to GLP toxicology, dose-ranging, and first-in-human studies for flavonoid–S1SCB combinations and liposomal formulations; compare with existing long-acting local anesthetic depots and evaluate non-opioid analgesia in surgical models.
Site 1 sodium channel blockers (S1SCBs), such as tetrodotoxin (TTX) and neosaxitoxin, are ultrapotent local anesthetics with low tissue toxicity. Their duration of action is relatively brief, but increasing the dose can lead to systemic toxicity. Here, we report that selected flavonoids-puerarin (PUE), naringenin, and kaempferol-prolong nerve block from S1SCBs 4- to 25-fold. Using both tympanic membrane (TM) permeation and sciatic nerve fluorescence distribution models, we demonstrate the flavonoids increase drug penetration across biological barriers (the TM and the barriers in and around nerve), suggesting that they act as chemical permeation enhancers (CPEs). Importantly, flavonoids exhibited minimal tissue toxicity compared to conventional CPEs. Coencapsulation of TTX and PUE into a liposomal delivery system further prolonged local anesthesia to over 25 d from a single injection. These findings establish flavonoid compounds as a safe class of CPEs and provide a platform of long-acting, nonopioid pain therapies. Flavonoids may be attractive alternatives to conventional CPEs in biomedical applications.
2. Plasma Biomarkers of Brain Injury in Critically Ill Children Receiving Extracorporeal Membrane Oxygenation.
In 219 critically ill children on ECMO, plasma GFAP and NfL rose in the 24–48 hours preceding imaging-confirmed new acute brain injury and were independently associated with unfavorable short-term outcomes. Tau did not show significant associations, positioning GFAP and NfL as leading candidates for real-time neurologic monitoring in pediatric ECMO.
Impact: Provides multicenter prospective evidence that two plasma biomarkers anticipate ABI and stratify outcomes during ECMO, addressing a major monitoring gap where neuro exams and imaging are limited.
Clinical Implications: Serial GFAP and NfL measurement could enable earlier ABI detection, risk stratification, and tailored neuroprotective strategies in pediatric ECMO, while avoiding overreliance on nonspecific markers.
Key Findings
- In ECMO courses with new ABI, GFAP and NfL increased 6.4% and 16.1% per 24 hours, respectively, before neuroimaging diagnosis.
- Higher first-sample and peak levels of GFAP, NfL, and tau were associated with unfavorable discharge outcomes, but only GFAP and NfL remained significant after adjustment.
- A two-fold rise in GFAP (aHR 1.48) and NfL (aHR 1.43) from first ECMO sample independently predicted unfavorable outcomes; tau showed no significant association.
Methodological Strengths
- Prospective multicenter cohort with serial biomarker sampling across 11 children's hospitals.
- Time-to-event modeling with adjusted hazard ratios accounting for baseline levels, age, and indication.
Limitations
- Observational design cannot establish causality; clinical protocols for biomarker-guided interventions were not tested.
- Generalizability to non-ECMO settings and different ECMO indications requires study; tau assay and timing may have limited sensitivity.
Future Directions: Validate GFAP/NfL thresholds and kinetics for ABI detection, integrate into real-time ECMO monitoring protocols, and conduct interventional trials testing biomarker-triggered neuroprotective strategies.
IMPORTANCE: Timely identification of acute brain injury (ABI) in children receiving extracorporeal membrane oxygenation (ECMO) support is critical for early neuroprotective interventions. OBJECTIVES: To determine if elevations in plasma glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and tau levels in children receiving ECMO precede new ABI confirmed by neuroimaging, and if they are associated with mortality and functional outcomes. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective observational cohort study conducted from 2019 to 2023, with 18-month follow-up completed in 2025. Children aged 2 days to younger than 18 years at ECMO cannulation were recruited from 11 US children's hospitals. Study data were analyzed from May to August 2025. EXPOSURES: GFAP, NfL, and tau measured in plasma samples collected serially during the ECMO course. MAIN OUTCOMES AND MEASURES: Unfavorable short-term outcome was a composite of in-hospital mortality or discharge Pediatric Cerebral Performance Category score of 3 or greater with decline of at least 1 point from baseline. Unfavorable long-term outcome was a composite of mortality or Vineland Adaptive Behavior Scales, third edition, composite score less than 85 at 18 months after ECMO. RESULTS: This study included 219 participants (224 ECMO courses; 1089 serial blood samples). Median age was 11 months (IQR, 30 days-9 years), and 121 (54%) were male. Among 60 ECMO courses with new ABI during the ECMO course, GFAP and NfL levels increased significantly, by 6.4% (95% CI, 1.4%-11.6%) and 16.1% (95% CI, 10.5%-22.0%), respectively, for each 24 hours preceding neuroimaging diagnosis of new ABI. Geometric means for GFAP, NfL, and tau were all significantly higher in those with unfavorable vs favorable outcome at hospital discharge for both the first sample receiving ECMO and peak levels during ECMO support. A 2-fold increase in GFAP and NfL levels from first sample receiving ECMO was significantly associated with unfavorable outcome after adjusting for baseline GFAP and NfL levels, age, and ECMO indication (GFAP adjusted hazard ratio [aHR], 1.48; 95% CI, 1.22-1.79; NfL aHR, 1.43; 95% CI, 1.14-1.79). Similar models for tau showed no significant association with outcomes. CONCLUSIONS AND RELEVANCE: Results suggest that GFAP and NfL may be promising candidates for real-time neurologic monitoring in children receiving ECMO and may aid in diagnosis, association with outcomes, and potentially guiding neuroprotective strategies.
3. Effects of lung protective ventilation and conventional ventilation on postoperative atelectasis in neonates under general anesthesia.
In a randomized trial of 100 neonates, lung-protective ventilation (tidal volume ~6 mL/kg, PEEP, and recruitment) significantly reduced significant postoperative atelectasis (18% vs 58%) and improved lung ultrasound scores at the end of surgery compared with conventional ventilation.
Impact: Directly informs intraoperative ventilation settings in a high-risk neonatal population using randomized evidence and objective lung ultrasound endpoints.
Clinical Implications: Adopting LPV (lower tidal volumes with PEEP and recruitment maneuvers) in neonatal anesthesia can reduce postoperative atelectasis; protocols should standardize ultrasound-based monitoring and balance oxygenation with volutrauma risk.
Key Findings
- LPV reduced significant postoperative atelectasis compared with conventional ventilation (18% vs 58%).
- Median lung ultrasound score at end of surgery was lower with LPV [7 (6, 9)] vs control [12 (8, 18)].
- Protocolized LPV (approximately 6 mL/kg Vt with PEEP and recruitment) was feasible during >2-hour neonatal procedures.
Methodological Strengths
- Randomized controlled design in a vulnerable neonatal population.
- Objective outcome assessment using standardized lung ultrasound scoring.
Limitations
- Single-center trial with modest sample size, limiting generalizability.
- Short-term endpoints at end of surgery; no long-term respiratory outcomes reported.
Future Directions: Multicenter RCTs to confirm benefits, define optimal PEEP/recruitment protocols, and assess longer-term pulmonary outcomes and safety in diverse neonatal subgroups.
BACKGROUND: General anesthesia frequently causes atelectasis, a condition that significantly endangers patient safety during and after surgery, especially in neonates. Evidence suggests that lung protective ventilation (LPV) strategies may reduce the incidence of postoperative atelectasis in patients receiving general anaesthesia; however, the efficacy for neonatal patients remains controversial. This study aims to explore how LPV affects the incidence of atelectasis in neonates. METHODS: This randomized controlled trial involved neonatal patients under general anesthesia with mechanical ventilation for over two hours, randomly assigned to receive LPV (including a Vt of 6 mL/kg, 5 cmH RESULTS: The study enrolled 100 neonatal patients, divided into 50 in the LPV group and 50 in the control group. At the conclusion of surgery, the LPV group had a significantly lower incidence of significant atelectasis (18% vs. 58%) and lower median LUS scores [7 [6, 9] vs. 12 [8, 18]] than the control group did (all CONCLUSIONS: Compared with conventional ventilation, LPV results in a significantly lower incidence of significant postoperative atelectasis and lower LUS scores in neonates receiving general anaesthesia. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, ChiCTR2100051721.